



PEER-REVIEW REPORT

Name of journal: *World Journal of Clinical Cases*

Manuscript NO: 88795

Title: Abemaciclib-induced lung damage leading to discontinuation in brain metastases from breast cancer: A Case report

Provenance and peer review: Unsolicited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 06178412

Position: Peer Reviewer

Academic degree: MD

Professional title: Doctor

Reviewer's Country/Territory: India

Author's Country/Territory: Japan

Manuscript submission date: 2023-10-11

Reviewer chosen by: AI Technique

Reviewer accepted review: 2023-10-12 01:52

Reviewer performed review: 2023-10-17 17:33

Review time: 5 Days and 15 Hours

| | |
|--|--|
| Scientific quality | <input checked="" type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish |
| Novelty of this manuscript | <input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Good <input type="checkbox"/> Grade C: Fair <input type="checkbox"/> Grade D: No novelty |
| Creativity or innovation of this manuscript | <input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Good <input type="checkbox"/> Grade C: Fair <input type="checkbox"/> Grade D: No creativity or innovation |



| | |
|---|--|
| Scientific significance of the conclusion in this manuscript | <input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Good <input type="checkbox"/> Grade C: Fair <input type="checkbox"/> Grade D: No scientific significance |
| Language quality | <input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection |
| Conclusion | <input checked="" type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection |
| Re-review | <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No |
| Peer-reviewer statements | Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous |
| | Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No |

SPECIFIC COMMENTS TO AUTHORS

1. Original Submission Recommendation to the author and editor: Minor revision
 Title: Manuscript ID: Manuscript NO: 06178412 entitled "Abemaciclib-induced lung damage leading to discontinuation in brain metastases from breast cancer: A Case report" Article Type: Case report
 2. Comments to the Corresponding Author:
 COPE Ethical guidelines followed during the review process, In this manuscript, authors described the problems associated with the limited therapeutic options for HER2-negative breast cancer patients with brain metastases. Authors elucidated a significant clinical case of a woman with ER-positive, HER2-negative breast cancer who exhibited an good therapeutic response to abemaciclib and letrozole therapy for brain metastases. However, this treatment had to be discontinued due to drug-induced lung damage (DILD). This report concluded the challenging balance between efficacy and adverse events in the management of brain metastases and highlights the significant requirement for the alternative treatment strategies in this patient population.
 Comments: Overview and general recommendation: The paper was well written. Yet, proofreading can enhance the quality of the manuscript. Several sentences need



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

rewriting to make the readers comfortable when reading this. 1. case report is novel and the authors should discuss about the Abemaciclib-induced prevalence of diarrhea and fatigue in comparison to palbociclib and ribociclib. Any adverse of hepatotoxicity reported in the patient ??? 2. In the MRI, I noticed the abemaciclib plus letrozole treatment mediated attenuation of the brain metastases and the contrast effect. The assessment indicated a therapeutic effect equivalent to partial response. 3. Is the patient postmenopausal female ?? mention in the manuscript 4. Enhance the discussion with the following articles
<https://aacrjournals.org/clincancerres/article/26/20/5310/82934/A-Phase-II-Study-of-Abemaciclib-in-Patients-with> <https://pubmed.ncbi.nlm.nih.gov/32694159/> Use endnote/Mendly for referencing Line by line proof reading is potentially required.

****Thank you****